<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Volitionrx Limited — News on 6ix</title>
<link>https://6ix.com/company/volitionrx-limited</link>
<description>Latest news and press releases for Volitionrx Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:12:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/volitionrx-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7944824982d98966dc4a2.webp</url>
<title>Volitionrx Limited</title>
<link>https://6ix.com/company/volitionrx-limited</link>
</image>
<item>
<title>VolitionRx Announces Acceptance of Compliance Plan by NYSE American</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-announces-acceptance-of-compliance-plan-by-nyse-american</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-announces-acceptance-of-compliance-plan-by-nyse-american</guid>
<pubDate>Thu, 23 Apr 2026 12:12:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange.</description>
</item>
<item>
<title>Volition Launches rNuQ™ Webshop Broadening Product Range</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-launches-rnuqtm-webshop-broadening-product-range</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-launches-rnuqtm-webshop-broadening-product-range</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over the past 10 years.</description>
</item>
<item>
<title>VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-secures-eur-20-million-of-non-dilutive-funding-from-regional-government-agencies-in-belgium</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-secures-eur-20-million-of-non-dilutive-funding-from-regional-government-agencies-in-belgium</guid>
<pubDate>Tue, 31 Mar 2026 12:16:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium.</description>
</item>
<item>
<title>Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-announces-mayo-clinic-study-demonstrates-nuqr-concentrations-are-elevated-in-trauma-patients</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-announces-mayo-clinic-study-demonstrates-nuqr-concentrations-are-elevated-in-trauma-patients</guid>
<pubDate>Mon, 30 Mar 2026 12:13:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma.</description>
</item>
<item>
<title>Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-announces-abstract-demonstrating-risk-stratification-in-lung-cancer-presented-at-the-european-lung-cancer-conference</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-announces-abstract-demonstrating-risk-stratification-in-lung-cancer-presented-at-the-european-lung-cancer-conference</guid>
<pubDate>Thu, 26 Mar 2026 12:17:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.</description>
</item>
<item>
<title>VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-limited-schedules-full-fiscal-year-2025-earnings-conference-call-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-limited-schedules-full-fiscal-year-2025-earnings-conference-call-and-business-update</guid>
<pubDate>Wed, 25 Mar 2026 20:12:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below.</description>
</item>
<item>
<title>Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-reports-breakthrough-in-liquid-biopsy-achievement-of-over-99percent-purity-in-isolating-cancer-dna</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-reports-breakthrough-in-liquid-biopsy-achievement-of-over-99percent-purity-in-isolating-cancer-dna</guid>
<pubDate>Wed, 18 Mar 2026 12:17:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".</description>
</item>
<item>
<title>Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-announces-first-ever-automated-nuqr-vet-cancer-test-with-fujifilm-vet-systems-27</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-announces-first-ever-automated-nuqr-vet-cancer-test-with-fujifilm-vet-systems-27</guid>
<pubDate>Fri, 06 Mar 2026 13:10:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, allowing use of full automation rather than manual plates in central laboratories.</description>
</item>
<item>
<title>VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution</guid>
<pubDate>Wed, 25 Feb 2026 13:10:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant clinical and commercial progress achieved over recent months.</description>
</item>
<item>
<title>Volition Announces the Appointment of New Distributor for Nu.Q® Discover</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-announces-the-appointment-of-new-distributor-for-nuqr-discover</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-announces-the-appointment-of-new-distributor-for-nuqr-discover</guid>
<pubDate>Tue, 10 Feb 2026 13:07:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan.</description>
</item>
<item>
<title>VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards</guid>
<pubDate>Mon, 09 Feb 2026 22:20:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if</description>
</item>
<item>
<title>Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-sponsors-symposium-at-15th-conference-of-the-european-hidradenitis-suppurativa-foundation</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-sponsors-symposium-at-15th-conference-of-the-european-hidradenitis-suppurativa-foundation</guid>
<pubDate>Wed, 04 Feb 2026 13:45:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February.</description>
</item>
<item>
<title>VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-limited-announces-the-preparation-of-reimbursement-submission-for-its-nuqr-cancer-assays</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-limited-announces-the-preparation-of-reimbursement-submission-for-its-nuqr-cancer-assays</guid>
<pubDate>Fri, 30 Jan 2026 13:50:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.</description>
</item>
<item>
<title>Volition Announces Data to Support Use of Nu.Q® NETs in New Indication</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-announces-data-to-support-use-of-nuqr-nets-in-new-indication</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-announces-data-to-support-use-of-nuqr-nets-in-new-indication</guid>
<pubDate>Tue, 27 Jan 2026 13:00:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population[1].</description>
</item>
<item>
<title>Volition Continues to Extend Access to Nu.Q® Vet Cancer Test</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-continues-to-extend-access-to-nuqr-vet-cancer-test</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-continues-to-extend-access-to-nuqr-vet-cancer-test</guid>
<pubDate>Tue, 20 Jan 2026 13:25:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool.</description>
</item>
<item>
<title>Volition Sponsors Symposium at Veterinary Meeting and Expo</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-sponsors-symposium-at-veterinary-meeting-and-expo</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-sponsors-symposium-at-veterinary-meeting-and-expo</guid>
<pubDate>Fri, 16 Jan 2026 13:45:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the world's leading veterinary education conference, Veterinary Meeting and Expo ("VMX") in Orlando, Florida.</description>
</item>
<item>
<title>VolitionRx Secures $2.0 Million in Funding</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-secures-dollar20-million-in-funding</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-secures-dollar20-million-in-funding</guid>
<pubDate>Thu, 08 Jan 2026 14:15:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind Global Asset Management XII LLC (the "Investor"), an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Under the Amended Agreement, the Company will receive aggregate gross proceeds of $2,000,000 from the Investor in e</description>
</item>
<item>
<title>VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats</title>
<link>https://6ix.com/company/volitionrx-limited/news/volitionrx-announces-breakthrough-clinical-data-for-nuqr-vet-cancer-test-in-cats</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volitionrx-announces-breakthrough-clinical-data-for-nuqr-vet-cancer-test-in-cats</guid>
<pubDate>Thu, 08 Jan 2026 13:45:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for f</description>
</item>
<item>
<title>Volition Issues Business Review 2025</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-issues-business-review-2025</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-issues-business-review-2025</guid>
<pubDate>Wed, 17 Dec 2025 13:45:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.</description>
</item>
<item>
<title>Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment</title>
<link>https://6ix.com/company/volitionrx-limited/news/volition-solves-liquid-biopsys-needle-in-a-haystack-problem-achieves-180-fold-18000percent-enrichment</link>
<guid isPermaLink="true">https://6ix.com/company/volitionrx-limited/news/volition-solves-liquid-biopsys-needle-in-a-haystack-problem-achieves-180-fold-18000percent-enrichment</guid>
<pubDate>Thu, 11 Dec 2025 14:00:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy". This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.</description>
</item>
</channel>
</rss>